UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/571,722	03/13/2006	Benjamin Mesequer	CH8412LeA36555	7780
Patent Departm	7590 04/09/200 nent	EXAMINER		
Lanxess Corporation 111 Ridc Park West Drive			NWAONICHA, CHUKWUMA O	
Pittsburgh, PA			ART UNIT	PAPER NUMBER
			1621	
CALORS STATE OF A STAT	V PERIOR OF PEOPLE			
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		04/09/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)					
Office Assis a Communication	10/571,722	MESEQUER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Chukwuma O. Nwaonicha	1621					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period with the set or extended period for reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on 03/13	3/06						
	action is non-final.						
•	,—						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-13</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-13</u> is/are rejected.							
7) Claim(s) is/are objected to.							
,	olocion requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:							
	1. ☑ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892) A) Interview Summary (PTO-413) Paper No(s)/Mail Date							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	ate atent Application						
Paper No(s)/Mail Date 6) Other:							

Application/Control Number: 10/571,722 Page 2

Art Unit: 1621

DETAILED ACTION

1. Claims 1-13 are pending in the application.

Priority

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3, 4 and 11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 3, 4 and 11 are indefinite because of improper dependency. Correction is required.

Claim 13 is indefinite because it depend on it self. Correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 13 provide for the process for the transition metal-catalyzed preparation, but, since the claim does not set forth any steps involved in the method/process, it is

unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a process without any active, positive steps delimiting how this use is actually practiced.

Claim 13 is rejected under 35 U.S.C. 101 because the claimed recitation of a process for the transition metal-catalyzed preparation, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 and 9-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Laue et al., {US 5,801,283}.

Laue et al. disclose applicant's claimed diphosphine compound of general formulas I and IV as shown below.

Application/Control Number: 10/571,722 Page 4

Art Unit: 1621

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-4 and 9-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sirges et al., {US 6,583,312} and Yokozawa et al., {JP 3146187}.

Applicants claim a diphosphine compounds of the general formula 1 and their use as ligand with metal to form complexes; wherein all the variables are as defined in the claims.

Application/Control Number: 10/571,722

Art Unit: 1621

formula 1

Determination of the scope and content of the prior art (M.P.E.P. §2141.01)

Sirges et al. teach diphosphine compound of formula 2; in which: R_3 is Ph, R_4 is H, R_5 is Cl, and R_6 is OMe. The diphosphine compound is employed as a ligand for the preparation of a metal complex.

formula 2

Yokozawa et al. teach diphosphine compound of formula 3; in which: R^1 is Ph, R^2 is lower alkyl, R^3 is halogen, R^4 is H and X is O. The diphosphine compound is employed as a ligand for the preparation of a metal complex.

Application/Control Number: 10/571,722

Art Unit: 1621

formula 2

Ascertainment of the difference between the prior art and the claims (M.P.E.P.. §2141.02)

Sirges et al. and Yokozawa et al. diphosphine compounds differ from the instantly claimed diphosphine compound in that the diphosphine compounds of Sirges et al. and Yokozawa et al. are subgenus of the instantly claimed diphosphine compound of the general formula 1. Specifically, applicants claimed diphosphine compound reads on diphosphine compound of Sirges et al. and Yokozawa et al. when the variables R'R" is Ph, B is lower alkyl and G is halogen.

<u>Finding of prima facie obviousness--rational and motivation (M.P.E.P.. §2142-2143)</u>

The instantly claimed diphosphine ligand and metal complex would have been suggested to one of ordinary skill because one of ordinary skill wishing to obtain diphosphine ligand and metal complex as a catalyst is taught to select the diphosphine compound from the genus of Sirges et al. and Yokozawa et al.

One of ordinary skill in the art would have a reasonable expectation of success in practicing the instant invention by varying the substituents on the genus of Sirges et al. and Yokozawa et al. to arrive at the instantly claimed diphosphine compound. Said person would have been motivated to practice the teaching of the reference cited because it demonstrates that diphosphine ligand and metal complex are useful as catalyst. The instantly claimed invention would therefore have been obvious to one of ordinary skill in the art.

Art Unit: 1621

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-13 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 copending Application No. 11/298,641 in view of Meseguer et al. This is a <u>provisional</u> obviousness-type double patenting rejection.

The presently claimed diphosphine compound is disclosed in U.S. Appl. No. 11/298,641.

Applicants claim a diphosphine compound; wherein all the variables are as defined in the claims while Application No. 11/298,641 teaches a diphosphine compound; wherein all the variables are as defined in the claims. See claims 1-13 of Application No. 11/298,641.

The conflicting claims are identical, and they are not patentably distinct from each other because the scope of the claims overlaps substantially with the scope of claims 1-13 in the copending Application No. 11/298,641, and the diphosphine

Art Unit: 1621

compound of the presently claim invention encompasses the diphosphine compound of the copending Application No. 11/298,641. Application No. 11/056,274 teaches the elements of the claimed invention with sufficient guidance, particularity, and with a reasonable expectation of success, that the invention would be *prima facie* obvious to one of ordinary skill in the art.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain <u>a</u> patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 4,8 and 10 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 4, 8 and 10 of Application No. 11/298,641. This is a double patenting rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chukwuma O. Nwaonicha whose telephone number is 571-272-2908. The examiner can normally be reached on Monday thru Friday, 8:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/571,722

Art Unit: 1621

Page 9

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chukwuma O. Nwaonicha, Ph.D. Patent Examiner Art Unit: 1621

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
-TECHNOLOGY CATER 1500

Thurman Page, Supervisory Patent Examiner,

Technology Center 1600